Acadia Pharmaceuticals Inc

NASDAQ: ACAD
$16.31
-$0.28 (-1.7%)
Closing price April 25, 2024
Acadia Pharmaceuticals Inc is a biopharmaceutical company based in San Diego, California, dedicated to developing and commercializing innovative medicines for central nervous system disorders and rare diseases. Its flagship product, NUPLAZID, treats hallucinations and delusions associated with Parkinson’s disease psychosis. Acadia is also advancing treatments for conditions like Rett Syndrome, schizophrenia, Prader-Willi syndrome, and Alzheimer’s disease psychosis, among others. The company, originally named Receptor Technologies, was founded in 1993 and emphasizes addressing unmet medical needs in neuropsychiatric conditions.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Wednesday, including DraftKings, H&R Block and Novartis.
Tuesday's top analyst upgrades and downgrades included AutoZone, Best Buy, Bloomin' Brands, EOG Resources, Lemonade, Micron Technology, QuantumScape, Stitch Fix and Twilio.
A new Stifel research report includes the firm's biotech stock picks for 2021. These five have the biggest upside to the posted price targets and are best suited for patient, aggressive growth...
Health care has been a top performer this year, and there is every reason to believe that performance will carry through into 2021. These are four of the highest-ranked health care ideas from the...
Monday's top analyst upgrades and downgrades included Bristol-Myers Squibb, Chewy, DraftKings, Exxon Mobil, McAfee, Nvidia, Square, Tilray and Walt Disney.
Tuesday's top analyst upgrades and downgrades included Crocs, Gap, GW Pharmaceuticals, Lowe's Companies, Merck, Nio, Palo Alto Networks, Phillips 66, Starbucks and Vital Farms.
Tuesday's top analyst upgrades and downgrades included Albertsons, Alphabet, Carnival, Coeur Mining, Devon Energy, Halliburton, Skyworks Solutions, Tesla, Walt Disney and Zendesk.
These nine stocks made big moves, up or down, after the close on Monday, July 20, 2020.
Canaccord Genuity recently released a report detailing some of the biggest biotech catalysts coming out over these next six months.
Thursday's top analyst upgrades and downgrades included Bed Bath & Beyond, Ciena, DocuSign, eHealth, Faceboook, Netflix, PNC Financial Services, Square, Tilray, Twitter and Zoom Video Communications.
Monday's top analyst upgrades, downgrades and initiations included Adobe, Amgen, Bank of America, Broadcom, CME, Goldman Sachs, Micron Technology, PepsiCo, UnitedHealth, Urban Outfitters and Vertex...
Thursday was a breakout day for a few biotech companies. Some made absolutely massive runs, while others fell off a cliff.
Here 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the month of December.
Acadia shares made a handy gain on Monday after the firm announced positive results from an eight-week Phase 2 study evaluating pimavanserin as a therapy for Parkinson’s disease patients with...
The top analyst upgrades, downgrades and initiations seen on Friday included Acadia Pharmaceuticals, Broadcom, CBOE Global Markets, Etsy, Gap, General Electric, Home Depot, Lowe's Companies, Oracle...